TY - JOUR
T1 - Nonmuscle invasive bladder cancer
T2 - a primer on immunotherapy
AU - Maruf, Mahir
AU - Brancato, Sam J.
AU - Agarwal, Piyush K.
N1 - Publisher Copyright:
Copyright © 2016 by Cancer Biology & Medicine
PY - 2016/6/1
Y1 - 2016/6/1
N2 - Intravesical Bacillus Calmette-Guérin (BCG) has long been the gold standard treatment of nonmuscle invasive bladder cancer. Recently, there has been an emergence of novel immunotherapeutic agents, which have shown promise in the treatment of urothelial cell carcinoma. These agents aim to augment, modify, or enhance the immune response. Such strategies include recombinant BCG, monoclonal antibodies, vaccines, gene therapy, and adoptive T-cell therapy. Here, we review the emerging immunotherapeutics in the treatment of nonmuscle invasive bladder cancer.
AB - Intravesical Bacillus Calmette-Guérin (BCG) has long been the gold standard treatment of nonmuscle invasive bladder cancer. Recently, there has been an emergence of novel immunotherapeutic agents, which have shown promise in the treatment of urothelial cell carcinoma. These agents aim to augment, modify, or enhance the immune response. Such strategies include recombinant BCG, monoclonal antibodies, vaccines, gene therapy, and adoptive T-cell therapy. Here, we review the emerging immunotherapeutics in the treatment of nonmuscle invasive bladder cancer.
KW - Bacillus Calmette-Guérin (BCG)
KW - Bladder cancer
KW - Immunotherapy
KW - Urothelial cell carcinoma
UR - http://www.scopus.com/inward/record.url?scp=84978898112&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84978898112&partnerID=8YFLogxK
U2 - 10.20892/j.issn.2095-3941.2016.0020
DO - 10.20892/j.issn.2095-3941.2016.0020
M3 - Review article
AN - SCOPUS:84978898112
SN - 2095-3941
VL - 13
SP - 194
EP - 205
JO - Cancer Biology and Medicine
JF - Cancer Biology and Medicine
IS - 2
ER -